Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
Main finding · Incident PDResult — go to the resultHazard ratio 0.70 95% CI 0.55–0.89Authors' conclusion
Compared to DPP4 inhibitors, SGLT2 inhibitors were associated with a significantly lower risk of incident PD in older populations with T2D.
Study context
- Population
- Medicare fee-for-service beneficiaries ≥65 years with T2D and without pre-existing Parkinson disease (PD), 2016–2020; mean age 75 ± 7 years, 52% women
- Participants
- 89,330 eligible beneficiaries
- Exposure
- SGLT2i initiation vs DPP-4i initiation
- Outcome
- Risk of PD
Methodological details1:1 propensity score matching, Medicare claims data
- 1:1 propensity score matching
- Medicare claims data
Main finding
Incident PD
Hazard ratio
0.70
95% CI 0.55–0.89
By group
SGLT2 inhibitorvs DPP4 inhibitor
HR 0.70 (95% CI 0.55–0.89)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Incident PD, overall cohort · over follow-up
- Incident PD among all eligible beneficiaries
- 0.6% (n = 537)
Incident PD by subgroup (non-Hispanic Black, insulin users)
- Potential trend of more profound risk reduction in non-Hispanic Black individuals and insulin users
Original publication
Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes. Diabetes Obes Metab. Published 10 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →